血清NSE、CYFRA21-1、pro-GRP及β2-MG在中晚期非小细胞肺癌诊疗中的应用价值

Application value of serum NSE, CYFRA21-1, pro-GRP and β2-MG in the diagnosis and treatment of medium and advanced non-small cell lung cancer

目的探讨神经元特异性烯醇化酶(NSE)、细胞角蛋白21-1(CYFRA21-1)、胃泌素释放肽前体(pro-GRP)、β2微球蛋白(β2-MG)在中晚期非小细胞肺癌诊疗中的临床价值。方法选取我院110例肺癌患者(观察组)、52例肺良性病变患者(良性组)、52例健康体检者(对照组)为受试对象,检测比较各组及观察组化疗前、后NSE、CYFRA21-1、pro-GRP及β2-MG水平。结果观察组血清NSE、CYFRA21-1、pro-GRP、β2-MG水平高于良性组和对照组(P<0.05),其中CYFRA21-1在鳞癌中高表达,β2-MG在腺癌中高表达,NSE及pro-GRP在小细胞肺癌中高表达。化疗后,观察组的NSE、CYFRA21-1、pro-GRP及β2-MG水平均降低(P<0.05)。四种标志物联合检测的灵敏度均高于单一指标检测。结论血清NSE、CYFRA21-1、pro-GRP、β2-MG水平可作为鉴别非小细胞肺癌及评估化疗效果的临床指标,联合检测可提高诊断的灵敏度。

Objective To investigate the clinical value of neuron-specific enolase (NSE), cytokeratin 21-1 (CYFRA21-1), gastrin-releasing peptide precursor (pro-GRP),β2 microglobulin (β2-MG) in the diagnosis and treatment of medium and advanced non-small cell lung cancer.Methods A total of 110 patients with lung cancer (observation group), 52 patients with benign pulmonary disease (benign group) and 52 healthy persons (control group) in our hospital were selected as objects.The levels of NSE, CYFRA21-1, pro-GRP and β2-MG were detected and compared in each group and the observation group before and after chemotherapy.Results The levels of serum NSE, CYFRA21-1, pro-GRP and β2-MG in the observation group were higher than those in the benign group and the control group (P<0.05), and CYFRA21-1 expressed highly in squamous cell carcinoma,β2-MG expressed highly in adenocarcinoma, NSE and pro-GRP expressed highly in small cell lung cancer.After chemotherapy, the levels of NSE, CYFRA21-1, pro-GRP and β2-MG in the observation group decreased (P<0.05).The sensitivity of combined detection of four markers was higher than that of single indicator detection.Conclusion The levels of serum NSE, CYFRA21-1, pro-GRP and β2-MG can be used as clinical indicators for differentiating non-small cell lung cancer and evaluating the efficacy of chemotherapy.Combined detection can improve the sensitivity of diagnosis.